Does Anthem Cover Forteo?

How Anthem Classifies Forteo on Its Formulary

Anthem places Forteo (teriparatide) on a specialty medication tier across the majority of its commercial, employer-sponsored, and Medicare Advantage formularies. This classification means higher cost-sharing and mandatory dispensing through a designated specialty pharmacy.

The specific tier varies by plan. Individual and family marketplace plans sold under the Anthem Blue Cross Blue Shield brand typically list Forteo on Tier 4 or Tier 5. Employer-sponsored plans may use a slightly different tier structure, but the drug almost always sits above standard brand-name medications. Medicare Advantage plans administered by Anthem follow CMS formulary guidelines and place teriparatide in the specialty tier with coinsurance rates that commonly range from 25% to 33% after the deductible is met 1.

Anthem's pharmacy benefit manager, IngenioRx (now integrated with Elevance Health's pharmacy operations), maintains a clinical policy bulletin for teriparatide that outlines specific coverage criteria. The drug is classified as medically necessary rather than experimental, which is an important distinction. Experimental classifications would make coverage nearly impossible to obtain. Forteo's FDA approval dates back to 2002, and the Endocrine Society's 2020 clinical practice guideline recommends anabolic therapy as first-line treatment for patients at very high fracture risk, a recommendation that strengthens coverage arguments [2].

One factor that influences Anthem's formulary placement: the availability of biosimilar teriparatide. The FDA approved a teriparatide biosimilar (Terrosa, marketed by Pfenex/Alvogen) and generic teriparatide options have entered the market. Some Anthem formularies now prefer these lower-cost alternatives, placing them on a more favorable tier while requiring step therapy through the biosimilar before approving brand-name Forteo.

Prior Authorization Requirements for Forteo Under Anthem

Anthem requires prior authorization for Forteo on essentially every plan type. The prescribing physician must submit documentation proving the patient meets specific clinical criteria before Anthem will approve coverage.

The standard Anthem prior authorization criteria for teriparatide include: a confirmed osteoporosis diagnosis with a DXA T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip; documented failure of, intolerance to, or contraindication to at least one oral bisphosphonate (typically alendronate or risedronate) used for a minimum of 12 months; and evidence of high fracture risk such as a prior fragility fracture, FRAX score indicating 10-year major osteoporotic fracture probability exceeding 20%, or hip fracture probability exceeding 3% 3.

Some Anthem plans bypass the bisphosphonate step-therapy requirement for patients who present with specific high-risk profiles. These include patients with multiple vertebral compression fractures, glucocorticoid-induced osteoporosis in those taking prednisone at 7.5 mg/day or higher for three or more months, and patients with DXA T-scores of -3.5 or lower. The American College of Rheumatology 2022 guideline for glucocorticoid-induced osteoporosis specifically recommends anabolic agents as initial therapy in high-risk patients on long-term glucocorticoids, and Anthem's policy language reflects this recommendation [4].

The prior authorization submission should include the DXA scan report (not just the T-score), a medication history showing bisphosphonate dates and reason for discontinuation, FRAX calculation results, and any imaging confirming prior fractures. Incomplete submissions are the most common reason for initial denials. Processing typically takes 5 to 15 business days for standard requests; urgent requests linked to acute fracture management may receive expedited review within 72 hours.

What You Will Pay Out of Pocket

The out-of-pocket cost for Forteo through Anthem depends on your plan's benefit design, deductible status, and whether you have access to copay assistance programs. The retail price for a 28-day supply of brand-name Forteo (teriparatide 20 mcg/dose pen) is approximately $4,100 without insurance.

With Anthem coverage after prior authorization approval, patients on commercial plans typically face one of these cost structures: a flat specialty copay of $100 to $250 per 28-day supply, or coinsurance of 20% to 33% of the negotiated rate. On a plan with 25% coinsurance and a negotiated price of $3,200, the per-month cost would be $800 before reaching the out-of-pocket maximum. Most Anthem commercial plans have annual out-of-pocket maximums between $4,000 and $8,550 for individual coverage (the 2026 ACA maximum is $9,200), which caps total exposure 5.

Medicare Advantage enrollees covered by Anthem face a different cost trajectory. Under the Medicare Part D benefit structure, teriparatide falls into the specialty tier with a 25% coinsurance during the initial coverage phase. Once the patient enters the coverage gap (after $5 to 030 in total drug costs for 2026), coinsurance rises to 25% of the negotiated price. Catastrophic coverage kicks in after $8 to 000 in true out-of-pocket spending, dropping costs to 5% coinsurance or $4.50/$11.20 copays for the remainder of the year.

Eli Lilly, the manufacturer of brand-name Forteo, operates the Forteo Savings Card program for commercially insured patients. Eligible patients can reduce their copay to as low as $4 per month for up to 24 months. This program does not apply to government insurance (Medicare, Medicaid, Tricare). Anthem does not restrict use of manufacturer copay cards, but some employer-sponsored plans using copay accumulator or copay maximizer programs may prevent manufacturer payments from counting toward the deductible or out-of-pocket maximum.

Generic teriparatide, now available from several manufacturers, carries a significantly lower list price. The average wholesale price for generic teriparatide pens ranges from $1,800 to $2,400 for a 28-day supply. Anthem formularies that prefer the generic will process it at a lower coinsurance base, potentially cutting patient costs by 30% to 50% compared to brand-name Forteo.

How to Manage an Anthem Denial for Forteo

Initial denials happen frequently. Anthem's own utilization management data suggests that between 20% and 35% of first-time prior authorization requests for specialty osteoporosis medications receive a "not medically necessary" determination, often due to incomplete documentation rather than genuine clinical ineligibility.

The first step after a denial is requesting the specific denial reason in writing. Anthem is required to provide this under ERISA (for employer plans) or state insurance regulations (for individual/small group plans). The denial letter will reference the clinical policy bulletin and identify exactly which criterion was not met.

For a first-level appeal, the prescribing physician should submit a peer-to-peer review request. This is a phone conversation between your doctor and an Anthem medical director. Data from the 2019 AMA Prior Authorization Physician Survey found that 73% of physicians reported that peer-to-peer conversations resulted in overturned denials at least some of the time [6]. During this call, the physician can clarify documentation, explain why bisphosphonate therapy is inappropriate, and cite current guideline recommendations.

Second-level appeals require more formal documentation. A letter of medical necessity should reference the Endocrine Society guidelines, the patient's individual fracture risk assessment, and any relevant literature supporting anabolic therapy. The VERO trial (N=1,360) demonstrated that teriparatide reduced new vertebral fractures by 56% compared to risedronate over 24 months (RR 0.44 to 95% CI 0.29 to 0.68), making it a strong evidence-based argument when bisphosphonate alternatives are the insurer's preferred treatment 7.

If internal appeals fail, patients in fully insured plans (not self-funded employer plans) can request an external independent review. External reviewers overturn osteoporosis drug denials at meaningful rates when the clinical documentation is strong. The entire appeals process, from initial denial to external review decision, typically spans 60 to 120 days.

Anthem Coverage for Forteo Alternatives

Anthem covers several alternative osteoporosis medications, and understanding the formulary hierarchy helps patients and providers make cost-effective decisions.

Oral bisphosphonates (alendronate, risedronate) sit on Tier 1 or Tier 2 of most Anthem formularies as generics. Monthly costs are $4 to $30. These are Anthem's first-line preference and the step-therapy gateway to Forteo. Alendronate 70 mg weekly is the most commonly prescribed first-line agent, and the Fracture Intervention Trial (FIT) demonstrated a 47% reduction in hip fracture risk over three years in women with existing vertebral fractures (N=2,027) [8].

Zoledronic acid (Reclast), an IV bisphosphonate given once yearly, typically requires prior authorization but sits on a lower specialty tier than Forteo. The HORIZON-PFT trial (N=7,765) showed that zoledronic acid reduced morphometric vertebral fractures by 70% and hip fractures by 41% over three years 9. Anthem considers this a step-therapy equivalent to oral bisphosphonates for patients who cannot tolerate oral formulations.

Denosumab (Prolia), a RANK ligand inhibitor given as a subcutaneous injection every six months, is covered on Anthem's specialty tier with prior authorization. It often has slightly lower cost-sharing than Forteo. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over three years compared to placebo 10. Anthem's clinical policy generally considers denosumab and teriparatide as separate therapeutic classes rather than substitutes, so failure on denosumab is not required before Forteo authorization.

Romosozumab (Evenity), a sclerostin inhibitor, is the newest anabolic agent for osteoporosis. Anthem covers it on the specialty tier with prior authorization and step therapy requirements similar to Forteo. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared to alendronate alone over 24 months 11. Anthem generally requires the same bisphosphonate failure documentation for romosozumab as for Forteo, though some plans allow direct access for patients with T-scores below -3.0.

Dr. Felicia Cosman, professor of clinical medicine at Columbia University, has noted: "Anabolic agents like teriparatide and romosozumab build new bone rather than simply slowing bone loss. For patients with severe osteoporosis and multiple fractures, starting with an anabolic agent before transitioning to an antiresorptive produces the best long-term skeletal outcomes" 12.

The 24-Month Treatment Window and Anthem's Authorization Timeline

The FDA limits teriparatide treatment to 24 months based on the original black-box warning derived from rat osteosarcoma data at supratherapeutic doses. Anthem's authorization structure mirrors this limit precisely.

Initial prior authorizations for Forteo through Anthem are typically granted for 6 to 12 months. Reauthorization requires updated documentation showing treatment response (follow-up DXA or bone turnover markers such as P1NP) and confirmation that the cumulative treatment duration has not exceeded 24 months. The prescribing physician should submit the reauthorization request 30 days before the current authorization expires to avoid gaps in therapy.

An important clinical nuance: the 24-month clock applies to lifetime cumulative exposure per the FDA label. Patients who previously received 12 months of teriparatide, discontinued, and now want to restart are limited to 12 additional months. Anthem's pharmacy system tracks cumulative dispensing, and requests exceeding 24 months total will be denied without exception. The 2020 Endocrine Society guideline recommends sequential therapy after completing the anabolic window, transitioning to a bisphosphonate or denosumab to preserve bone density gains [2].

The osteosarcoma risk that prompted the original FDA warning has not been confirmed in human studies. A 15-year post-marketing surveillance study published in the Journal of Bone and Mineral Research (the Forteo Patient Registry, N=75,247) found no increase in osteosarcoma incidence among teriparatide users compared to background population rates 13. The FDA removed the black-box warning in 2020 but retained the 24-month recommended duration.

After completing teriparatide, bone density gains can erode within 12 to 24 months without follow-on antiresorptive therapy. The DATA-Switch extension study showed that women who transitioned from teriparatide to denosumab continued gaining bone density, while those who stopped treatment without an antiresorptive lost approximately half their lumbar spine BMD gains within two years 14. Anthem covers the transition to denosumab or bisphosphonate therapy after Forteo completion without requiring a new step-therapy sequence.

Anthem Medicaid Managed Care and Forteo Access

Anthem administers Medicaid managed care plans in multiple states, and coverage criteria for Forteo vary by state Medicaid formulary requirements.

In states where Anthem operates Medicaid managed care (including Indiana, California, Georgia, Kentucky, and Virginia among others), teriparatide coverage follows state-specific preferred drug lists. Some state Medicaid programs classify teriparatide as a physician-administered drug under the medical benefit rather than the pharmacy benefit, which changes the prior authorization pathway and cost-sharing structure.

Medicaid patients generally face lower out-of-pocket costs than commercial plan members. Federal rules cap Medicaid copays for specialty drugs, and many states have zero-copay policies for injectable osteoporosis medications. The prior authorization clinical criteria, however, tend to be stricter than commercial plan criteria. Several state Medicaid formularies require documentation of two bisphosphonate failures (rather than one) and a fragility fracture history before authorizing teriparatide.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) position statement has advocated for removing excessive step-therapy barriers to anabolic osteoporosis therapies, particularly for high-risk patients who have already sustained fractures [15]. This position has influenced some state Medicaid programs to create expedited authorization pathways for patients with documented hip or vertebral fractures.

Tips for Getting Anthem to Approve Forteo

A strategic approach to the prior authorization process significantly increases approval rates. These specific steps apply to Anthem plans across all product lines.

Submit a complete prior authorization packet on the first attempt. Include the full DXA report (not an interpretation letter), pharmacy records showing bisphosphonate fill dates and duration, documented adverse effects from bisphosphonates (GI intolerance, esophageal issues, atypical femoral fracture risk), imaging of any prior fractures, and the FRAX score printout. Missing a single element commonly triggers an automatic denial.

Dr. Andrea Singer, director of bone densitometry at MedStar Georgetown University Hospital, has recommended: "When submitting prior authorization for anabolic therapy, always include the patient's absolute fracture risk calculation and not just the T-score. A T-score of -2.5 in a 55-year-old with no other risk factors carries very different clinical weight than the same T-score in a 75-year-old with prior fractures and glucocorticoid use" 16.

Request the generic teriparatide rather than brand-name Forteo if your Anthem plan's formulary prefers it. This small change can shift the drug to a more favorable tier and reduce the prior authorization burden. Some Anthem formularies auto-approve generic teriparatide with fewer documentation requirements than the brand.

Track your authorization timeline carefully. Anthem must respond to standard prior authorization requests within 15 business days for commercial plans and 72 hours for Medicare Advantage Part D requests. If Anthem misses these deadlines, coverage defaults to approval in many states under prompt-decision regulations.

Consider requesting a formulary exception if Forteo is not on your plan's formulary at all. Under ACA regulations, all marketplace and fully insured plans must have an exceptions process. The prescribing physician must document that formulary alternatives are medically inappropriate for the specific patient. Anthem's formulary exception forms are available through the provider portal or by calling the pharmacy prior authorization line at the number on the back of the member's ID card.

Patients prescribed teriparatide 20 mcg daily via subcutaneous injection should receive their first dose training from a healthcare provider, and Anthem covers the associated office visit under standard outpatround benefit codes (CPT 96372 for therapeutic injection administration and J3110 for teriparatide drug coding when billed under the medical benefit).